Published in Brain on August 01, 1997
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Paraneoplastic syndromes of the CNS. Lancet Neurol (2008) 4.62
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77
Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry (2006) 2.52
Paraneoplastic neurological syndromes. Orphanet J Rare Dis (2007) 2.32
Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry (2001) 1.91
Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol (2014) 1.25
Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol (2005) 1.24
Paraneoplastic neurological syndromes. Clin Exp Immunol (2014) 1.12
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer (2011) 1.10
Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol (2005) 1.07
Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci U S A (2008) 1.03
Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis (2011) 1.02
Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One (2013) 1.01
VGCC antibody-positive paraneoplastic cerebellar degeneration presenting with positioning vertigo. Neurol Sci (2011) 0.97
The clinical spectrum of Caspr2 antibody-associated disease. Neurology (2016) 0.97
'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation (2015) 0.94
'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation (2015) 0.92
Anti-yo associated paraneoplastic cerebellar degeneration in a man with large cell cancer of the lung. Case Rep Neurol Med (2013) 0.91
Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol (2012) 0.87
Paraneoplastic syndromes in patients with primary head and neck cancer. Eur Arch Otorhinolaryngol (2007) 0.87
18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol (2009) 0.83
Voltage-gated calcium channel autoimmune cerebellar degeneration: Case and study of cytotoxicity. Neurol Neuroimmunol Neuroinflamm (2016) 0.80
The ataxic Cacna1a-mutant mouse rolling nagoya: an overview of neuromorphological and electrophysiological findings. Cerebellum (2009) 0.79
Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol (2007) 0.78
Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurol Sci (2009) 0.78
Understanding the physiopathology of paraneoplastic and genetic cerebellar ataxia. J Neurol Neurosurg Psychiatry (2006) 0.78
Regulation of neurovascular coupling in autoimmunity to water and ion channels. Autoimmun Rev (2014) 0.78
Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev (2017) 0.78
Acquired ataxias: the clinical spectrum, diagnosis and management. J Neurol (2015) 0.77
Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases (2015) 0.77
Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung. BMJ Case Rep (2013) 0.77
Autoimmune channelopathies of the nervous system. Curr Neuropharmacol (2011) 0.76
Cell-mediated immune responses in paraneoplastic neurological syndromes. Clin Dev Immunol (2013) 0.76
Neuronal central nervous system syndromes probably mediated by autoantibodies. Eur J Neurosci (2016) 0.75
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol (2016) 0.75
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome. Mol Neurobiol (2014) 0.75
Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer. J Cancer Res Clin Oncol (2007) 0.75
Paraneoplastic limbic encephalitis with late-onset magnetic resonance imaging findings: A case report. Mol Clin Oncol (2017) 0.75
[Small cell lung cancer]. Wien Klin Wochenschr (2007) 0.75
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain (2000) 7.95
Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology (2007) 6.61
Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol (1983) 5.98
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci (1997) 4.50
Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer (1982) 4.40
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (2009) 3.68
A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med (1999) 3.58
Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology (2010) 3.40
HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell (1991) 3.33
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med (2001) 3.26
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21
Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry (2007) 3.12
Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis (2009) 3.11
Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology (1992) 3.11
Distribution of brain metastases. Arch Neurol (1988) 3.11
Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol (1978) 3.08
Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology (2008) 2.85
Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron (1993) 2.81
IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology (2012) 2.78
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77
The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain (1988) 2.73
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol (1990) 2.58
Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med (1990) 2.54
[Structural quality of acute internal medicine rheumatology clinics--Project Group of the Association of Rheumatologic Acute Clinics]. Z Rheumatol (2002) 2.54
Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53
Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry (2006) 2.52
Cerebrovascular complications in patients with cancer. Medicine (Baltimore) (1985) 2.39
Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet (1981) 2.36
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain (1980) 2.36
Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain (1999) 2.35
Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain (2001) 2.34
Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol (1974) 2.33
Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology (2011) 2.32
Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome) Lancet (1991) 2.28
Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology (2008) 2.27
Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology (2006) 2.25
Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol (2001) 2.24
Effect of brain irradiation on demyelinating lesions. Neurology (1993) 2.21
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol (1997) 2.17
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol (2001) 2.15
Insights into antibody-associated encephalitis--Bickerstaff's 1950's papers revisited. J Neurol Sci (2013) 2.13
Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology (1979) 2.13
Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry (1985) 2.11
Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. J Neurol Neurosurg Psychiatry (2007) 2.10
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A (2000) 2.08
Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol (1991) 2.08
Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol (2001) 2.06
Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1987) 2.05
P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology (2002) 2.05
Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol (1999) 2.03
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol (2003) 2.01
SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology (2007) 2.00
Analysis of relapses in anti-NMDAR encephalitis. Neurology (2011) 1.98
Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol (1998) 1.97
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors. Cancer (1990) 1.97
Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet (1995) 1.94
Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med (1967) 1.93
Intracranial metastases from systemic cancer. Adv Neurol (1978) 1.92
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum (2000) 1.91
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91
Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol (2001) 1.90